Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIONOXX INC. is managing a workload of 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners, which indicates a high level of diversity in the prosecution experience. The workload is further spread across 5 distinct art units, suggesting that the company's pharmaceutical technology is broad and touches many different specialized examination groups. This distribution requires the company to coordinate a complex strategy to ensure consistency across many different USPTO divisions.
The busiest examiner, DRISCOLL, LORA E BARNHART, is responsible for 1 busiest examiner pending action. This is just one of the 6 pending office actions currently active for the company. With 6 distinct examiners and 5 distinct art units, the company must manage multiple timelines and examiner preferences simultaneously. The Biotechnology & Pharmaceuticals portfolio is clearly undergoing a wide-ranging examination process, providing the company with a wealth of feedback from different technical perspectives across the 5 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 3 (43%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | ALAM, DANYAL HASSAN | 26d |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | EBBINGHAUS, BRIANA NOEL | — |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638144 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS | DENT, ALANA HARRIS | 23d overdue |
| 18281884 | VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO | DRISCOLL, LORA E BARNHART | — |
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | CORNET, JEAN P | — |
| 17638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | BLUMEL, BENJAMIN P | — |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | EBBINGHAUS, BRIANA NOEL | — |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 3991 | 1 |
| 1628 | 1 |
| 1643 | 1 |
| 1632 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281884 | VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO | DRISCOLL, LORA E BARNHART | 3991 | §112 | Final Rejection | — | Pending | Sep 13, 2023 |
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | CORNET, JEAN P | 1628 | §103 | Non-Final OA | — | Pending | Aug 08, 2022 |
| 17638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | BLUMEL, BENJAMIN P | 1671 | §103 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | ALAM, DANYAL HASSAN | 1671 | §101§103 | Non-Final OA | 26d | Pending | Feb 24, 2022 |
| 17638144 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | 23d overdue | Pending | Feb 24, 2022 |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2021 |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Aug 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial